BIGTINCAN HOLDINGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.16 AUD | +6.67% |
|
0.00% | -20.00% |
| Apr. 11 | Bigtincan Holdings Logs AU$30 Million Revenue in Fiscal Q3; Shares Surge 19% | MT |
| Mar. 18 | Bigtincan Holdings Limited(ASX:BTH) dropped from S&P/ASX All Ordinaries Index | CI |
| Sales 2024 * | 124M 81.63M | Sales 2025 * | 122M 80.81M | Capitalization | 98.6M 65.16M |
|---|---|---|---|---|---|
| Net income 2024 * | -9M -5.95M | Net income 2025 * | 5M 3.3M | EV / Sales 2024 * | 0.66 x |
| Net cash position 2024 * | 16.59M 10.96M | Net cash position 2025 * | 14.08M 9.3M | EV / Sales 2025 * | 0.69 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
17.8
x | Employees | 495 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bigtincan Holdings Limited
More press releases
| 1 day | +6.67% | ||
| Current month | +6.67% | ||
| 1 month | +10.34% | ||
| 3 months | -15.79% | ||
| 6 months | -41.82% | ||
| Current year | -20.00% |
1 week
0.15
0.16
1 month
0.140.19
Current year
0.140.26
1 year
0.140.65
3 years
0.141.53
5 years
0.141.60
10 years
0.141.60
| Managers | Title | Age | Since |
|---|---|---|---|
David Keane
FOU | Founder | - | 10-12-31 |
Patrick Welch
PSD | President | - | 11-12-31 |
Vivian Stewart
COO | Chief Operating Officer | - | 14-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Inese Kingsmill
BRD | Director/Board Member | - | 21-10-05 |
Wayne Stevenson
BRD | Director/Board Member | - | 16-09-27 |
David Keane
FOU | Founder | - | 10-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 0.16 | +6.67% | 6,433,361 |
| 24-05-02 | 0.15 | +3.45% | 301,705 |
| 24-05-01 | 0.145 | -3.33% | 960,415 |
| 24-04-30 | 0.15 | 0.00% | 124,849 |
| 24-04-29 | 0.15 | 0.00% | 590,700 |
Delayed Quote Australian S.E., May 03, 2024 at 02:10 am EDT
More quotes
Beta Pharmaceutical Limited is a Australia-based biopharmaceutical company. The Company is focused on the identification, development and commercialization of products and therapies targeting the chemoprevention and treatment of breast cancer. The Company is working in collaboration with scientists at the College of Pharmacy, University of Louisiana at Monroe in southern the United States of America (ULM) to develop cancer chemopreventive agents using natural phytonutrients, called tocotrienols as treatments for breast cancers. Funded by Beta Pharmaceutical Limited, the applied research programme with ULM includes four laboratories and is known as the Breast Cancer and Health Project, which has been underway.
Calendar
2024-08-26
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.16
AUD
Average target price
0.39
AUD
Spread / Average Target
+143.75%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.00% | 60.47M | |
| +25.69% | 48.09B | |
| +46.90% | 40.62B | |
| -3.46% | 40.43B | |
| -6.20% | 28.36B | |
| +9.17% | 24.89B | |
| -20.42% | 19.01B | |
| +28.07% | 12.09B | |
| +0.17% | 11.88B | |
| -1.24% | 11.8B |
- Stock Market
- Equities
- BTH Stock
